- Home
- DPRO vs CHRO Comparison
DPRO vs CHRO Comparison
Compare DPRO & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPRO
- CHRO
- Stock Information
- Founded
- DPRO 1998
- CHRO 2002
- Country
- DPRO Canada
- CHRO United States
- Employees
- DPRO N/A
- CHRO N/A
- Industry
- DPRO Aerospace
- CHRO
- Sector
- DPRO Industrials
- CHRO
- Exchange
- DPRO Nasdaq
- CHRO Nasdaq
- Market Cap
- DPRO 10.4M
- CHRO 8.4M
- IPO Year
- DPRO N/A
- CHRO 2024
- Fundamental
- Price
- DPRO $1.77
- CHRO $0.93
- Analyst Decision
- DPRO Strong Buy
- CHRO Strong Buy
- Analyst Count
- DPRO 2
- CHRO 1
- Target Price
- DPRO $6.00
- CHRO N/A
- AVG Volume (30 Days)
- DPRO 247.4K
- CHRO 84.7K
- Earning Date
- DPRO 05-08-2025
- CHRO 05-13-2025
- Dividend Yield
- DPRO N/A
- CHRO N/A
- EPS Growth
- DPRO N/A
- CHRO N/A
- EPS
- DPRO N/A
- CHRO N/A
- Revenue
- DPRO $4,716,450.00
- CHRO N/A
- Revenue This Year
- DPRO $94.01
- CHRO N/A
- Revenue Next Year
- DPRO $95.14
- CHRO N/A
- P/E Ratio
- DPRO N/A
- CHRO N/A
- Revenue Growth
- DPRO 7.90
- CHRO N/A
- 52 Week Low
- DPRO $1.55
- CHRO $0.45
- 52 Week High
- DPRO $7.01
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- DPRO 39.67
- CHRO 34.93
- Support Level
- DPRO $1.63
- CHRO $0.92
- Resistance Level
- DPRO $1.93
- CHRO $1.05
- Average True Range (ATR)
- DPRO 0.11
- CHRO 0.10
- MACD
- DPRO 0.02
- CHRO 0.00
- Stochastic Oscillator
- DPRO 46.67
- CHRO 6.58
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.